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Aplidint (APL) is a new antitumoral drug from marine origin currently in phase II clinical trials against a wide multiplicity of cancers. As
resistance may be, as with other drugs, an important obstacle to the APL therapeutic efficacy, we have established an acquired
resistance cellular model by continuous exposure of HeLa cells to the drug. The stably resistant subline generated (HeLa-APL),
possessing more than 1000-fold relative resistance to APL than parental cells, did not show crossresistance to a subset of clinically
relevant antitumoral agents. In addition, resistance was not related to overexpression of P-glycoprotein or differences in overall drug
accumulation. Comparing to parental cells, HeLa-APL cells did not present either significant differences in the growth rate or apparent
alterations in the cell cycle distribution. Aplidint induced rapid and persistent phosphorylation of both JNK and p38 MAPKs, resulting
in activation of the mitochondrial apoptotic pathway in parental cells, but, notably, in HeLa-APL-resistant cells MAPKs activation only
occurred in a slight and transiently manner, failing to activate the above-mentioned apoptotic machinery. These results suggest that
sustained activation of JNK and p38 is essential for triggering the apoptotic programme induced by APL and that HeLa-APL cells
bypass this apoptotic response by preventing the specific mechanisms that prime and sustain the long-term activation of these
signalling cascades. Although far from human tumour physiology in vivo, HeLa-APL cells represent a potentially useful tool in gaining
insights into the mode of action of APL, in selecting non-crossresistant APL structural analogues, as well as in investigating and
developing methods to prevent resistance to this drug.
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Aplidint (APL, a macrocyclic depsipeptide, C57H87N7O15)
(Figure 1) is a novel antitumoral agent isolated from the marine
tunicate Aplidium albicans (Sakai et al, 1996; Rinehart, 2000).
Aplidint was developed as an antineoplastic agent because of its
potent antitumour activity in preclinical models against a wide
variety of human tumours (Faircloth et al, 1998, 1999). Clinical
trials with APL were initiated in 1999 in different locations of
Europe and Canada. Results from phase I clinical trials showed
signs of clinical benefit, in terms of stabilisation of the disease, and
a favourable tolerability profile, with mild and relatively infrequent
side effects (Anthoney et al, 2000; Armand et al, 2001; Bowman
et al, 2001; Mauroun et al, 2001; Ciruelos et al, 2002). In addition,
based on recent results showing that APL presents selective
cytotoxicity in vitro against childhood leukaemia cells, a phase I
clinical trial to study the effect of APL in pediatric leukaemia is
under implementation (Bresters et al, 2003; Erba et al, 2003).
Aplidint is currently in phase II clinical trials for renal, head and
neck, pancreas, lung (NSCLC) and colorectal cancers, and
medullary thyroid carcinoma. Recently, both the European Agency
for the Evaluation of Medicinal Products (EMEA) and the
American Food and Drug Administration (FDA) awarded APL
‘orphan drug’ status for the treatment of acute lymphoblastic
leukaemia (ALL).
There is little information about the mode of action of the drug
in tumour cells. Aplidint induces an early oxidative stress
response, which results in a rapid and sustained activation of the
epidermal growth factor receptor (EGFR), the nonreceptor protein
tyrosine kinase Src, and the serine/threonine kinases c-jun N-
terminal kinase (JNK) and p38 MAPK. These early events rapidly
trigger the induction of the mitochondrial apoptotic pathway via
cytochrome c release, activation of the caspase cascade and
activation of protein kinase C (PKC)-d, which seems to exert an
important effector role in mediating the cellular death induced by
the drug (Garcia-Fernandez et al, 2002; Cuadrado et al, 2003).
Some recent data indicate that, in leukaemic cells, APL action is
mediated, at least in part, through Fas/CD95 cell death receptor, a
member of the tumour necrosis factor (TNF) receptor family
(Gajate et al, 2003). Depending on the cell system, APL induces
either a very rapid apoptotic death without previous cell cycle
arrest, or causes a block in G1 and/or a delay in the progression
from S to G2/M phases of the cell cycle (Erba et al, 1999, 2002;
Garcia-Fernandez et al, 2002). As part of its antitumoral action in
leukaemic cells, APL inhibits the activity of ornithine decarbox-
ylase (ODC), an enzyme responsible for polyamine biosynthesis
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sand involved in cellular transformation (Paasinen-Sohns and
Holtta, 1997; Erba et al, 1999; Iwata et al, 1999), and causes a
reduction in vascular endothelial growth factor (VEGF) secretion
and downregulation of its receptor, VEGFR-1 (flt-1), involved in
the process of vascularisation and growth of certain tumours
(Taraboletti et al, 2002; Broggini et al, 2003). In addition, it has
been described that the APL closely related homologue didemnin B
inhibits protein synthesis (Crampton et al, 1984) and may interact
with elongation factor 1a (Crews et al, 1994) and palmitoyl
thioesterase (Crews et al, 1996). However, no primary target for
APL has been defined to date.
Drug resistance is a major obstacle to successful chemotherapy,
and occurs to most commonly used antitumoral drugs as well as
with the new target-oriented anticancer agents. As APL represents
a novel antitumoral compound currently undergoing clinical
studies, little is known about the possible mechanisms of intrinsic
or acquired resistance to this drug. Considering the clinical
interest of APL, we set out a project to obtain cell lines resistant to
the compound. This paper describes the establishment and
characterisation of a human carcinoma cell line, HeLa-APL, made
resistant to APL after continuous exposure to increasing
concentrations of the drug. Although HeLa-APL-resistant cells
represent an in vitro model that is far from human tumour
physiology, they can be potentially useful in the study of the
mechanism of action of APL in tumour cells, in the selection of
non-crossresistant APL structural analogues, and even to investi-
gate and develop methods to prevent resistance to this drug
in vivo.
MATERIALS AND METHODS
Reagents and antibodies
Aplidint (C57H87N7O15, MW: 1109.6), aplidin-dimethylaminocou-
marin (APL-dmac) (C62H89N7O15, MW: 1172.41), didemnin B
(C57H89N7O15, MW: 1112.354) and tamandarin A (C54H85N7O14,
MW: 1056.291) were manufactured at PharmaMar, SA. Stock
solutions (1mgml
 1 in DMSO) were prepared and stored at
 201C. All other reagents used in this study were of molecular
biology grade. Sulphorhodamine B (SRB), trizma, hoechst-33342,
propidium iodide, paclitaxel, etoposide, camptothecin, adriamy-
cin, vinblastine, cisplatin, 5-azacytidine, 6-thioguanine, fludara-
bine, 6-mercaptopurine, melphalan, chlorambucil, mitoxantrone
and amsacrine were purchased from Sigma (St Louis, MO, USA).
Calcein-AM was purchased from Calbiochem (Cambridge, MA,
USA). DMEM, penicillin, streptomycin and foetal calf serum were
purchased from Invitrogen (Carlsbad, CA, USA).
Anti-JNK1 (sc-474), anti-ERK2 (sc-154), anti-p38 MAPK (sc-
535), anti-PARP (sc-7150), anti-(pro)caspase-3 (sc-7148) and anti-
nPKC-d (sc-937) polyclonal antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phospho-p38
(#9211), anti-phospho-JNK (#9251), anti-phospho-PKC-d (Thr505)
(#9374), anti-phospho-PKC-d (#9376) (Ser643) (polyclonal) and
anti-phospho-ERK (#9106) (monoclonal) antibodies were pur-
chased from Cell Signaling Technologies, Inc (Beverly, MA, USA).
Anti-p170pgp/MDR (#MS-660-P0) monoclonal antibody was
purchased from Neo Markers (Fremont, CA, USA).
Cell culture
HeLa, HeLa-APL, LoVo and LoVo-dox (Grandi et al, 1986) cells
were maintained in DMEM supplemented with 10% FCS and
100Uml
 1 penicillin and streptomycin at 371C and 5% CO2.
Microscopy
Cells were stained with APL-dmac, Calcein-AM or Hoechst-33342
by direct addition of the fluorescent compounds in the cell culture
dishes, incubated at 371C for the times indicated, washed in PBS
and examined by fluorescence microscopy.
Determination of cell survival
Cells were washed twice with PBS, fixed for 15min in 1%
glutaraldehyde solution, rinsed twice in PBS, and stained in 0.4%
SRB solution for 30min at room temperature. Cells were then
rinsed several times with 1% acetic acid solution and air-dried.
Sulphorhodamine B was then extracted in 10mM trizma base
solution and the absorbance measured at 490nm. Cell survival was
expressed as percentage of control cell growth.
Flow cytometry analysis
The ploidy determination of nuclei was estimated by flow
cytometry DNA analysis. Cells were washed in PBS, fixed by
dropwise addition of 1ml of cold 70% ethanol and allowed to stand
on ice for 10min. Cell pellet was resuspended in 200ml of PBS
containing 10mgml
 1 RNAse A and incubated at 371C for 30min.
Propidium iodide (200mgml
 1) was added and the DNA content
per nucleus was evaluated in a FACscan flow cytometer (Becton-
Dickinson). For the analysis, only signals from single nuclei were
considered (10
4nucleiassay
 1).
Western blotting
Cells were washed in PBS, collected and resuspended in lysis buffer
(20mM Tris–HCl (pH 7.5), 150mM NaCl, 1% (vv
 1) Nonidet P-40,
2m M EDTA, 1mM PMSF, 10mgml
 1 aprotinin and 10mgml
 1
leupeptin) and kept on ice for 15min. Cell extracts were cleared by
microcentrifugation at 14000g for 30min at 41C. Equal amounts of
extracts were resolved in SDS–PAGE and electroblotted to
activated PVDF membranes (Immobilon-P, Millipore) following
standard techniques (Sambrook et al, 1989). Membranes were
sequentially probed with primary and appropriate secondary
(horseradish-peroxidase-conjugated) antibodies following the
manufacturer’s instructions. Antibody–antigen complexes were
detected using the ECL system (Amersham Biosciences, NJ, USA).
Maldi TOF mass spectrometry
To detect minute amounts of APL present in the cellular extracts,
Matrix-Assisted Laser Desorption/Ionisation-Time Of Flight Mass
Spectrometry (Maldi-TOF MS) technique was used. Cell cultures
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Figure 1 Molecular structure of Aplidint (APL).
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swere treated with vehicle or APL at the concentrations and times
indicated in the text, washed with PBS and harvested by
centrifugation at 6000r.p.m. for 5min at 41C. Cell pellets were
washed with PBS and extracted with cold methanol. Equal amounts
of extract were applied on a template, air dried, mixed with 0.2–
0.5ml matrix (10mgml
 1 dihydroxy benzoic acid in water:
acetonitrile mix, 1% trifluoroacetic acid) and air dried. Analyses
were performed on a Voyager DE Pro (PerSeptive Biosystems,
Framingham, MS, USA). Mass spectra were averaged over 100–200
laser shots from a nitrogen laser (337nm) operating in a linear
mode. Ionised molecules were accelerated with a voltage of 20kV.
The following peptides were used as external markers: intact
human insulin, human insulin alpha-chain, human insulin beta-
chain and cytochrome c.
RESULTS
HeLa cells were selected because of its high sensitivity to APL
among several cell lines tested in our laboratory. HeLa cells were
continuously exposed to increasing concentrations of APL over a
period of more than 1 year. Initial treatment started at 0.5nM
(aprox. five times the IC50 at 72h) and was stepwise increased until
450nM was reached. Viable cells surviving at this proapoptotic
concentration were established and designated HeLa-APL. The
morphology and growth features of HeLa-APL cell line were
comparable to those of the parental wild-type cells, showing a
comparable doubling time (about 24h while exponentially
growing). In the presence of 450nM APL, HeLa-APL cells showed
a rather delayed growth (Figure 2A). By flow cytometric analysis
after DNA staining with propidium iodide, log-phase HeLa-APL
cells did not present apparent alterations in the cell cycle
parameters as compared to the parental HeLa cells (Figure 2B).
Using the SRB growth inhibition assay, HeLa-APL showed stable
41000-fold increase in the relative resistance factor to APL at the
IC50 level (Figure 2C). Resistance was not reversed while
maintaining the cell line in drug-free medium for at least 3
months (not shown).
Treatment of parental HeLa cells with 450nM APL induced
progressive chromatin condensation and the appearance of typical
apoptotic bodies (as revealed by fluorescent staining of chromatin
with permeable Hoechst-33342) that resulted in massive cell death
as early as 6h post-treatment (Figure 3A, left). By flow cytometry
analysis, it was correlated with a rapid and progressive accumula-
tion of hypodiploid cells in the sub-G1 region (apoptotic cells,
arrows) and a delayed progression through S to G2/M phase of the
cell cycle (arrow heads) (Figure 3B, left). When HeLa-APL cells
were treated with APL under the same conditions, neither signs of
apoptotic population (Figure 3A, right) nor perturbations in the
cell cycle (Figure 3B, right) were observed at any of the time points
studied.
Aplidint has been shown to rapidly induce the mitochondrial
apoptotic pathway via rapid and persistent activation of JNK and
p38 MAPK (Garcia-Fernandez et al, 2002; Cuadrado et al, 2003).
Since APL appeared to be unable to induce apoptosis in HeLa-
APL-resistant cells, we studied the molecular effects of APL in both
cell systems. Wild-type and resistant cells were treated with 450nM
APL for different times and the expression of proteins involved in
the induction and execution of apoptosis were analysed by
Western blotting. Results showed that, in parental HeLa cells,
APL induced rapid (around 5min) and persistent JNK and p38
MAPK phosphorylation, as expected. By contrast, in HeLa-APL-
resistant cells, only a very weak and transient JNK and p38 MAPK
activation was observed after drug treatment, indicating that
sustained activation of stress-activated MAPKs plays an essential
role in mediating the cytotoxic effects of APL in tumour cells
(Figure 4A). It was also previously reported that APL activates ERK
(p42/p44-MAPK) phosphorylation, in a time-dependent biphasic
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Figure 2 Comparison of Hela wt and Hela APL cells. (A) Time-course
analysis of HeLa wt and HeLa-APL cell growth in the absence (vehicle) or
presence of 450nM APL. Cells were treated with APL for the indicated
times and cell survival determined by sulphorhodamine B colorimetric
assay. Results are expressed as percentage control growth. (B) Cell cycle
distribution of exponentially growing HeLa wt and HeLa-APL cells, as
analysed by flow cytometry. (C) Relative sensitivity of HeLa wt and HeLa-
APL cells to APL. Cells were untreated (vehicle) or treated with the
indicated concentrations of APL for 24, 48 and 72h, and cell survival was
determined by sulphorhodamine B colorimetric assay. Results are
expressed as mean percentage of control growth 7 s.e.m. (bars) of three
independent experiments. Arrows indicate 50% control growth.
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Figure 4 Time-dependent effects of APL on MAPKs and caspase cascade. HeLa wt and HeLa-APL cells were treated with vehicle alone or 450nM APL
for the indicated time periods (min) and JNK, p38 MAPK and ERK (p42/p44) (A) or caspase-9, caspase-3, PARP and PKC-d (B) protein status analysed by
Western blotting. Membranes were reprobed with antibodies against total JNK, p38 MAPK, ERK (p42/p44) and PKC-d for normalisation.
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Figure 3 Time-dependent effects of APL on chromatin integrity and DNA ploidy. HeLa wt and HeLa-APL cells were treated with vehicle alone or 450nM
APL for the indicated time periods. (A) Phenotypic changes induced by APL as analysed by fluorescence microscopy after chromatin staining with Hoechst
33342. (B) Time course of APL-induced apoptosis as analysed by flow cytometry. Sub-Gl, hypodiploid population (arrows) and delayed progression through
S phase (arrowheads) are indicated.
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smanner in HeLa parental cells. Interestingly, first peaking at
15min post-treatment appeared similarly in both cell systems,
while second peaking at around 6h post-treatment was absent in
HeLa-APL-resistant cells (Figure 4A). Remarkably, no changes in
the level of protein expresion were detected after re-probing blots
against total JNK and p38 MAPK in either case, indicating that APL
induced phosphorylation of pre-existing MAPKs and not promot-
ing de novo protein synthesis. Immunoblotting analysis of proteins
involved in the initiation and execution of apoptosis showed
activation of caspase-9 and -3, inactivation of PARP (emergence of
cleaved 85kDa fragment) and concomitant cleavage and phos-
phorylation of PKC-d (40kDa proteolytic product phosphorylated
at Thr
505). Consistently with previously shown morphological
appearance and cell cycle analysis results, none of these molecular
events were observed in HeLa-APL-resistant cells, indicating the
complete absence of apoptotic response after treatment with
supraphysiologic concentrations of APL (Figure 4B).
Decreased drug accumulation is often associated with resistance
of tumour cells to anticancer drugs and frequently involves
overexpression of drug efflux proteins, P-glycoprotein (Pgp
170)
being the most common pump related to drug resistance
(Germann, 1996; Gottesman et al, 2002). The expression of
Pgp
170/MDR was studied in both parental and resistant cells by
Western blotting. As a positive control, we used the multidrug-
resistant cell line LoVo-Dox, a colorectal carcinoma cell line
overexpressing Pgp
170 after long-term exposure to doxorubicin.
LoVo parental cells, which do not express Pgp
170, were also
included (LoVo wt). As shown in Figure 5A, no detectable
expression of Pgp
170 was observed in HeLa or HeLa-APL cells
under either untreated or APL-treated conditions (6h). By
contrast, Pgp
170 protein was strongly expressed in LoVo-Dox
cells. Its expression was not altered by APL treatment. The absence
of a Pgp
170 acting in HeLa-APL cells was further confirmed by the
use of the permeable substrate calcein-AM, which, after intracel-
lular cleavage by unspecific esterases, accumulates in the cell and
become impermeable and highly fluorescent. As a control system,
we used again LoVo and LoVo-Dox cells. Calcein-AM accumulates
in LoVo-sensitive cells, but was excluded from resistant LoVo-Dox
cells. Pre-incubation of cell cultures with 50mM verapamil (vp), a
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Figure 5 Role of P-glycoprotein (Pgp
170) in HeLa-APL acquired
resistance. (A) HeLa wt, HeLa-APL, LoVo and LoVo-dox cells were
treated with vehicle alone or 450nM APL for 6h and Pgp
170 protein
expression analysed by Western blotting. (B) LoVo wt, LoVo-dox and
LoVo-dox cells pretreated with 50mM verapamil (LoVo-dox þ vp), were
loaded with Calcein-AM for 1h and then analysed by fluorescence
microscopy. (C) HeLa wt and HeLa-APL cells were treated with vehicle
alone or 450nM APL for the indicated time periods, loaded with Calcein-
AM for 1h and analysed by fluorescence microscopy.
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Figure 6 Intracellular accumulation of APL in HeLa wt and HeLa-APL
cells. (A) Molecular structure of fluorescent derivative APL-dimethylami-
nocoumarin (APL-dmac). (B) Hela wt and HeLa-APL cells were treated
with vehicle alone or 450nM APL-dmac for 1h and then analysed by
fluorescence microscopy. Dimethylaminocoumarin was used as back-
ground control in HeLa wt cells (dmac). Representative images are shown.
(C) Maldi-TOF analysis of APL in HeLa wt and HeLa-APL cells after
treatment with vehicle or 450nM APL for 1h. For clarity, only
chromatograms corresponding to APL are shown. Exact masses of peaks
corresponding to APLþH, APLþNa and APLþK ionised forms are
indicated (when detected). (D) Summary of APL and APL-dmac ionised
forms detected in HeLa wt and HeLa-APL cells, e.m., exact mass.
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spotent Pgp
170 inhibitor, resulted in accumulation of calcein-AM in
LoVo-Dox-resistant cells to an extent similar to that observed
in sensitive LoVo cells, demonstrating the effectiveness of the
fluorescent marker to assess for Pgp
170 action (Figure 5B).
Accumulation of fluorescent calcein-AM was consistent in both
HeLa parental and HeLa-APL-resistant cells (Figure 5C). Further-
more, APL treatment did not modify the fluorescent pattern in
either case, even after the apoptotic programme became apparent
in HeLa-sensitive cells (Figure 5C, arrows). However, since other
efflux pumps may contribute to decreased accumulation of APL in
HeLa-APL cells (Borst et al, 2000; Gottesman et al, 2002), we used a
fluorescent APL derivative (APL-dmac, see Materials and meth-
ods) (Figure 6A) with cytotoxic activity similar to that of APL (not
shown) (Ding et al, 2001). Results showed that internalisation and
accumulation of APL-dmac in the cytoplasmic compartment was
consistent in both cell systems (Figure 6B). Background fluores-
cence accumulation was assessed by using dimethylaminocoumar-
in alone (Figure 6B, dmac), which showed no detectable
fluorescent signal under the same conditions. Aplidint-dmac
remained internalised after long-term treatment (not shown). To
more precisely demonstrate the integrity of the drug after
intracellular accumulation, we used highly sensitive Maldi-TOF
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Figure 7 Relative sensitivity of HeLa wt and HeLa-APL cells to a panel of anticancer drugs. Triplicate plates of HeLa wt and HeLa-APL cells were exposed
to vehicle alone or the indicated concentrations of doxorubicin, etoposide, cisplatin, paclitaxel, vinblastine, camptothecin, 5-azacytidine, fludarabine, 6-
mercaptopurine and 6-thioguanine for 48 or 72h (as indicated). Cell survival was determined by sulphorhodamine B colorimetric assay. Results are
expressed as percentage control growth 7 s.e.m. Arrows indicate 50% control growth.
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smass spectrometry (Marvin et al, 2003). The presence of APL in
both parental and HeLa-APL-resistant cell systems after 1h
exposure was confirmed, as demonstrated by the detection of the
different ionised forms of APL, that is, B1110 for APLþH, B1132
for APLþNa and B1148 for APLþK. (Figure 6C and D).
Consistently, APL-dmac was also detected in both cell lines
(Figure 6D).
The pattern of sensitivity of parental and resistant cells and
crossresistance were determined for a series of standard anticancer
drugs (cisplatin, etoposide, doxorubicin, paclitaxel, vinblastine,
camptothecin, 5-azacytidine, 6-thioguanine, fludarabine and 6-
mercaptopurine) and two additional members of the didemnin
family with cytotoxic activity comparable to that of APL (Vervoort
and Fenical, 2000; Joullie et al, 2003), didemnin B and tamandarin
A. Notably, no significant crossresistance was observed with any of
the standard anticancer drugs tested, as determined by IC50 values
in the SRB cell growth assay (Figure 7). On the other hand,
comparable crossresistance was observed with the APL structural
analogues didemnin B and tamandarin A (Figure 8).
DISCUSSION
A human carcinoma cell line with acquired resistance to APL, a
new anticancer drug currently undergoing extensive phase II
clinical studies, has been established by continuous exposure to
stepwise increasing concentrations of the drug. HeLa-APL cells
showed more than 1000-fold stable resistance to APL than the
parental HeLa cells at the IC50 value. Clinical resistance may be
demonstrably more subtle, reflecting only 2–5-fold changes, but
differences in in vitro models are more dramatic due to the
intensive artificial selection for resistant subclones. When
comparing the chemosensitivity of HeLa-APL cells to other
commonly used anticancer drugs, no significant crossresistance
was observed with doxorubicin, cisplatin, etoposide, paclitaxel,
vinblastine, camptothecin, 5-azacytidine, 6-thioguanine, fludara-
bine and 6-mercaptopurine (as well as amsacrine, melphalan,
chlorambucil or mitoxantrone, not shown). A trend for cross-
resistance for APL and 20,20-difluorodeoxycytidine (gemcitabine)
in human leukaemia samples has been recently reported (Bresters
et al, 2003), but not with other antimetabolites, as occurred herein
with those tested in HeLa-APL cells (5-azacytidine, 6-thioguanine,
fludarabine and 6-mercaptopurine). By contrast, HeLa-APL cells
were equally resistant to didemnin B and tamandarin A, two
closely related APL structural analogues, demonstrating that HeLa-
APL-resistant cells have developed a specific resistance mechanism
against didemnins (Vervoort and Fenical, 2000; Joullie et al, 2003).
On the other hand, the lack of crossresistance with other
anticancer agents may reflect differences in its mode of action or
cellular pharmacology, and suggests the possibility to treat
relapsed or resistant cancers to conventional therapies with APL
and vice versa.
Drug resistance is often associated with decreased drug
internalisation or increased drug efflux and can involve over-
expression of drug efflux pumps (Germann, 1996; Gottesman et al,
2002). However, no Pgp
170 protein expression or activity was
observed in either parental or resistant cell line even after APL
treatment. The participation of other mechanisms related to
decreased drug accumulation was precluded given the following
observations: (i) fluorescent APL accumulates to the same extent
in both cell lines; (ii) conserved sensitivity to different commonly
used cytotoxic drugs, most of them exported by Pgp
170, MRP or
other unspecific pumps (Gottesman et al (2002) and references
therein); (iii) APL was detected by high-sensitivity mass spectro-
metry in both cell systems, an observation that, in addition, also
rules out the possibility of a resistance mechanism due to changes
in the intracellular metabolism of the drug.
We have previously shown that APL induces rapid and
sustained activation of JNK and p38 MAPK in tumour cells, and
this activation is pivotal to establish and maintain the apoptotic
programme (Garcia-Fernandez et al, 2002; Cuadrado et al, 2003).
The timing of JNK and p38 MAPK activation may be of crucial
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simportance, being a persistent rather than transient activation
associated with apoptosis (Chen et al, 1996a,b; Brenner et al,
1997). Long-lasting stimulation of stress MAPKs has been
described for different forms of stress-induced apoptosis (Xia
et al, 1995; Chen et al, 1996b, 1999; Herr et al, 1997; Luo et al, 1998;
Bacus et al, 2001). When comparing both cell lines, we found that,
contrary to wild-type cells, in resistant HeLa-APL cells, APL
treatment only induce a weak and transient activation of both JNK
and p38 MAPK and fails to activate the downstream apoptotic
cascade. This indicates the essential role of these two MAPKs in
priming the apoptotic programme induced by the drug. It has been
recently demonstrated that cells lacking JNK expression (jnk1/2
 / )
are much less sensitive to APL than their normal counterparts,
pointing out the crucial role of JNK in APL-induced apoptosis
(Cuadrado et al, 2004). Previous observations suggested that the
rapid activation of JNK and p38 MAPK is most probably due to an
early cellular oxidative imbalance generated by the drug, as
demonstrated by the protective effects of some antioxidants
(Garcia-Fernandez et al, 2002; Cuadrado et al, 2003). The lack of
MAPK activation upon drug treatment may indicate that resistant
cells have developed a specific mechanism to overcome APL-
mediated oxidative imbalance and the subsequent sustained
activation of the stress cascade. Although no direct correlation
between GSH content and APL sensitivity has been published to
date, GSH would appear as a putative sensor for APL action that
has to be further examined in HeLa-APL-resistant cells. Similar
mechanisms have been reported previously (Whelan et al, 1989;
Miyanishi et al, 2001; Cao et al, 2003). Concerning APL-mediated
ERK activation, we previously concluded that, in general, it was
not necessary for the cytotoxic action of the drug and that, most
probably, it was serving a protective role against the insult caused
by the drug (Garcia-Fernandez et al, 2002). In the present work, we
demonstrate a similar early ERK activation in both parental and
resistant HeLa-APL cells after drug treatment, confirming the
protective role of this rapid and transient ERK activation. We were
curious about the delayed ERK activation observed, and hypothe-
tised that it could be due to late activation of the MEK-ERK
pathway by PKC-d, a link that has been previously reported (Ueda
et al, 1996). Herein we show that in HeLa-APL-resistant cell line,
APL, does not induce either PKC-d or delayed ERK activation,
further supporting the above-mentioned hypothesis.
Mitochondria and caspases have key roles in apoptosis and it
was considered whether HeLa-APL cell line had subresponsive
apoptotic pathways. We show herein that HeLa-APL cells had
intact response to a number of caspase-dependent death inducers
like doxorubicin, camptothecin, paclitaxel or etoposide, and
therefore most likely had an intact apoptosis execution machinery,
further indicating that the alteration was upstream of caspase
activation.
In conclusion, the work presented herein describes the first
example of the generation of a cell line that is resistant to APL,
which is currently undergoing clinical trials. A number of potential
mechanisms for the resistance was ruled out, including those
involving altered drug transport, accumulation, metabolism or
subresponsive apoptotic pathways. HeLa-APL cells represent a
potentially useful tool in gaining insights into the mode of action
of APL in tumour cells, in selecting non-crossresistant APL
structural analogues, as well as to investigate and develop methods
to prevent resistance to this drug.
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